DOI:
10.1055/s-00050348
Indian Journal of Medical and Paediatric Oncology
LinksClose Window
References
Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee JL, Fong L. et al.
Pembrolizumab as second-line therapy for advanced urothelial carcinoma.
N Engl J Med 2017;
376: 1015-26
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.